Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case

Multi-kinase inhibitor sorafenib is the only one drug which increases life time in patients with advanced hepatocellular carcinoma (HCC). Results from the SHARP trial showed that median progression-free survival was less than 5 months. However, it is possible to achieve strong treatment effect for s...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Yu V Bisovskaya, V V Breder, B M Medvedeva, V A Gorbunova
Formato: Artigo
Idioma:Russo
Publicado: IP Habib O.N. 2014-06-01
Series:Современная онкология
Assuntos:
hepatocellular carcinoma
sorafenib
chronic hepatitis b
lamivudine
Acceso en liña:https://modernonco.orscience.ru/1815-1434/article/view/26969
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares